Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience-Reference-Cited by-同舟云学术

Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience

Published:2018 Issue: Volume:10 Page:55-56
ISSN:2213-0489
Container-title:Leukemia Research Reports
language:en
Short-container-title:Leukemia Research Reports

Author:

Ganguly Siddhartha^ORCID,Uvodich Mason,Dias Ajoy,McGuirk Joseph P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference6 articles.

1. Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course;McClure;Br. J. Haematol.,1999

2. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53;Kanagal-Shamanna;Cancer,2012

3. Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature;Hernández-Boluda;Leuk Lymphoma,2000

4. Isochromosome 17q10 associated with basophilia in primary myelofibrosis while with JAK2 inhibitor;Koumas;Ann. Hematol.,2015

5. Schweizerische arbeitsgemeinschaft für klinische krebsforschung (SAKK) and the German CML study group. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML study IV;Fabarius;Blood,2011

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders – Epidemiological Features and Overview;Frontiers in Oncology;2021-11-16

2. Ponatinib both as an effective bridge to allogeneic hematopoietic stem cell transplantation and as posttransplant maintenance therapy in a chronic myeloid leukemia patient with myeloid blast crisis;Hematology, Transfusion and Cell Therapy;2021-06